# A Phase 1B Investigator Initiated Study of Safety and Tolerability of Dexamethasone (D) in Combination With Venetoclax-based Low-Intensity Therapy (LIT) in Treatment-Naïve Acute Myeloid Leukemia (AML): DLIT-AML

> **NCT07014462** · PHASE1 · ENROLLING_BY_INVITATION · sponsor: **University of Vermont** · enrollment: 20 (estimated)

## Conditions studied

- AML - Acute Myeloid Leukemia

## Interventions

- **DRUG:** Dexamethasone plus Venetoclax-based Low-Intensity Therapy

## Key facts

- **NCT ID:** NCT07014462
- **Lead sponsor:** University of Vermont
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-09-01
- **Primary completion:** 2029-06
- **Final completion:** 2029-06
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07014462

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07014462, "A Phase 1B Investigator Initiated Study of Safety and Tolerability of Dexamethasone (D) in Combination With Venetoclax-based Low-Intensity Therapy (LIT) in Treatment-Naïve Acute Myeloid Leukemia (AML): DLIT-AML". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07014462. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*